BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 17220786)

  • 1. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
    Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
    Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
    Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus.
    Warnock GL; Meloche RM; Thompson D; Shapiro RJ; Fung M; Ao Z; Ho S; He Z; Dai LJ; Young L; Blackburn L; Kozak S; Kim PT; Al-Adra D; Johnson JD; Liao YH; Elliott T; Verchere CB
    Arch Surg; 2005 Aug; 140(8):735-44. PubMed ID: 16103282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
    Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin independence of unstable diabetic patient after single living donor islet transplantation.
    Matsumoto S; Okitsu T; Iwanaga Y; Noguchi H; Nagata H; Yonekawa Y; Yamada Y; Nakai Y; Ueda M; Ishii A; Yabunaka E; Shapiro JA; Tanaka K
    Transplant Proc; 2005 Oct; 37(8):3427-9. PubMed ID: 16298617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
    Paisley AN; Savage MW; Wiles PG
    Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
    Froud T; Faradji RN; Pileggi A; Messinger S; Baidal DA; Ponte GM; Cure PE; Monroy K; Mendez A; Selvaggi G; Ricordi C; Alejandro R
    Transplantation; 2008 Jul; 86(1):36-45. PubMed ID: 18622276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes.
    Fung M; Thompson D; Shapiro RJ; Warnock GL; Andersen DK; Elahi D; Meneilly GS
    Diabetes Res Clin Pract; 2006 Nov; 74(2):189-93. PubMed ID: 16621111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
    Fineman MS; Shen LZ; Taylor K; Kim DD; Baron AD
    Diabetes Metab Res Rev; 2004; 20(5):411-7. PubMed ID: 15343588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success.
    Koh A; Senior P; Salam A; Kin T; Imes S; Dinyari P; Malcolm A; Toso C; Nilsson B; Korsgren O; Shapiro AM
    Transplantation; 2010 Feb; 89(4):465-71. PubMed ID: 20177350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
    Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
    Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreas islet transplantation in patients with type 1 diabetes mellitus after kidney transplantation.
    Gonzalez Molina M; Alonso A; Briones R; Fernandez N; Caballero A; Miranda JM; Navarro A; Castro MJ; Burgos D; Cabello M; Sola E; Escaño A; Muñoz J
    Transplant Proc; 2005 Apr; 37(3):1443-5. PubMed ID: 15866632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).
    Zhou Z; Li X; Huang G; Peng J; Yang L; Yan X; Wang J
    Diabetes Metab Res Rev; 2005; 21(2):203-8. PubMed ID: 15386806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.